Deriving acceptable limits for non-mutagenic impurities in medicinal products - Durational adjustments
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.New analysis supports durationally adjusted qualification thresholds for unqualified non-mutagenic impurities (NMIs) in pharmaceuticals. This approach ensures patient safety during clinical development and aligns with 3Rs principles for impurity qualification.
Area Of Science
- Pharmaceutical Science
- Toxicology
- Regulatory Science
Background
- ICH Q3A/B guidelines lack durationally adjusted qualification thresholds for impurities during clinical development.
- A key principle of ICH Q3A is that 1 mg/day lifetime exposure to unqualified non-mutagenic impurities (NMIs) is considered safe.
Purpose Of The Study
- To analyze in vivo toxicology data and determine if durationally adjusted qualification limits for NMIs are supported.
- To evaluate the safety basis for existing and potentially new qualification thresholds based on dosing duration.
Main Methods
- Analysis of in vivo toxicology data from 4878 unique chemicals with established No Observed Adverse Effect Levels (NOAELs).
- Application of allometric scaling, a conservative approach, to NOAEL data from chronic, sub-acute, and sub-chronic toxicology studies.
Main Results
- Allometric scaling confirmed the safety basis for the 1 mg/day qualification threshold for NMIs in ICH Q3A.
- Supported durationally adjusted limits of 20 mg/day (less than one month) and 5 mg/day (greater than one month) for unqualified NMIs.
Conclusions
- The findings support the implementation of durationally adjusted NMI qualification thresholds.
- These adjusted thresholds enhance patient safety during pharmaceutical development and support the 3Rs (Replacement, Reduction, Refinement) in impurity qualification using new approach methods.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
When drugs are administered extravascularly, a comprehensive evaluation through noncompartmental analysis becomes imperative. This analytical approach considers various parameters that play a crucial role in understanding the pharmacokinetics of these drugs.
One of the key parameters is the mean transit time (MTT), which refers to the total duration required for drug molecules to transit through the body. MTT is determined by calculating the ratio of the area under the moment curve to the area...